Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Plasticell Signs Technology Agreement with Sigma-Aldrich

Published: Tuesday, November 30, 2010
Last Updated: Tuesday, November 30, 2010
Bookmark and Share
Collaboration to produce novel turnkey solution for stem cell research.

Plasticell, the biotechnology company specializing in high throughput technologies for directed stem cell differentiation, has announced the signing of a collaboration agreement with Sigma-Aldrich, a leading provider of technologies and reagents to the life science research market.

In the collaboration, Sigma-Aldrich will use its CompoZr® Zinc Finger Nuclease Technology to engineer various human stem cell lines that enable tracking of differentiation to specific mature cell types via fluorescent reporters, integrated directly into developmentally expressed genes. The technology enables highly efficient, precisely targeted knock-in of reporters, resulting in more reliable reporter systems than conventional transgenic methods which integrate reporters randomly throughout the genome. Plasticell will then use these cell lines in its CombiCult™ high throughput screening (HTS) system to develop novel stem cell differentiation protocols.

Under the Agreement, Plasticell will own resulting protocols for high efficiency, directed differentiation of stem cells, with Sigma-Aldrich marketing the reporter stem cell lines. Cells and media may be commercialized together in kits, while reporter cell lines can be linked to specific CombiCult™ screens, for optimized differentiation of human embryonic stem cells (ESC) or induced pluripotent cells (iPSC).

“I am very pleased to bring together Plasticell’s CombiCult™ and Sigma-Aldrich’s CompoZr® as part of this exciting collaboration,” said Dr. Yen Choo, Plasticell’s CEO, who has at various times been involved in the development of both technologies. Prior to founding Plasticell, Dr. Choo was founder and CSO of Gendaq Ltd (Sangamo UK), the biotechnology company that developed the zinc finger engineering system now used in CompoZr®. Zinc Finger Nucleases were listed in the Top 10 Innovations by The Scientist in 2008 and 2009, while Plasticell’s CombiCult™ HTS system was awarded the European Technology Innovation Award by Frost & Sullivan in 2010.

Plasticell’s Senior Scientist, Dr. Marina Tarunina, added: “We have already demonstrated that using fluorescent reporter lines in CombiCult™ experiments offers a highly convenient, real-time, visual readout for stem cell differentiation. Providing reporter cells as part of CombiCult™ enables us to offer industry partners a complete ‘turnkey’ solution for HTS with stem cells, ideally suited for in-house screening of compound libraries within pharmaceutical companies.”

Carl Schrott, Director of Marketing for Stem Cell Research Products at Sigma-Aldrich, said: “Efficient, directed differentiation of stem cells to predetermined cell lineages remains a major challenge in the field of ESCs and iPSCs. We are pleased to partner with stem cell differentiation experts Plasticell to develop complementary products that address this rapidly growing market segment.”

The present collaboration is supported by a Technology Strategy Board Regenerative Medicine Competition grant to a consortium led by Plasticell and including Sigma-Aldrich and Queen Mary University, London.

Financial terms were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich Announces Agreement on Assets Sale to Honeywell
Asset sale includes Sigma-Aldrich-branded solvents and inorganics business in the EEA.
Tuesday, October 20, 2015
Sigma-Aldrich Stockholders Approve Merck Acquisition
The transaction, expected to close mid-2015, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including regulatory approvals.
Monday, December 08, 2014
SAFC Expands Continuous Flow Capabilities
Sigma-Aldrich custom manufacturing services business unit, SAFC® Commercial, has installed a new commercial-scale continuous flow reactor at its Sheboygan, WI facility.
Wednesday, May 21, 2014
Sigma-Aldrich® Partners with Scripps Research Institute
The agreement marks first partnership of its kind between a research institution and reagents company.
Friday, July 19, 2013
Sigma Life Science to Distribute Olink Bioscience's Protein-Protein Interaction Assay
The products complement Sigma's antibody, RNAi and gene editing technologies.
Tuesday, February 12, 2013
Sigma-Aldrich Completes Acquisition of BioReliance
Sigma-Aldrich Corporation completes its acquisition of BioReliance Holdings, Inc. for $350 million in cash.
Wednesday, February 01, 2012
Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
Sigma Life Science announces that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at sageresearchmodels.com in late 2011.
Thursday, February 03, 2011
Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
Company’s CompoZr® cell lines ranked second as The Scientist magazine unveils this year’s best life science innovations.
Monday, December 06, 2010
Sigma® Life Science Enters Genetically Modified Cell Market
Sigma Life Science launches range of engineered cell lines exploiting CompoZr® zinc finger nuclease technology.
Monday, September 06, 2010
Sigma® Life Science and Switchgear Genomics to Co-Develop Simplified Novel MicroRNA Target Validation System
SwitchGear Genomics and Sigma’s lentiviral technology combined to simplify miRNA target validation, enabling researchers to investigate gene regulation.
Tuesday, August 10, 2010
Sigma-Aldrich Licenses from NeuroSurvival Technologies a Marker for Molecular Imaging of Apoptosis in Vivo
The marker, Apo-TRACE™, offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine.
Wednesday, February 27, 2008
Sigma-Aldrich Grants Pfizer Non-Exclusive Worldwide License to Use ddRNAi in Research Programs
The license enables Pfizer to undertake research activities throughout its global operations using ddRNAi technology.
Thursday, January 04, 2007
Sigma-Proligo Expands into Genopole® d'Evry Biopark
Sigma-Proligo provides researchers with high-quality oligonucleotides due to a high throughput synthesis platform.
Friday, October 20, 2006
Sigma-Aldrich Announces Service Provider for WGA Technology
Sigma announces MOgene as its first service provider of the GenomePlex® Whole Genome Amplification technology.
Wednesday, May 31, 2006
Sigma-Aldrich Sponsors Full-Text Article on High Content Viral Library Screens
The authors reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 27, 2006
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!